Get startedLog in
    Picture of Lineage Cell Therapeutics logo

    LCTX — Lineage Cell Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousSmall CapNeutral
    All News

    Brief: Opregen® 36-Month Visual Acuity Results Featured At Clinical Trials At The Summit 2025

    Picture of Lineage Cell Therapeutics logoLineage Cell Therapeutics
    23/06/2025 12:10
    June 23 (Reuters) - Lineage Cell Therapeutics Inc LCTX.A:

OPREGEN® (RG6501) 36-MONTH VISUAL ACUITY RESULTS FEATURED AT CLINICAL TRIALS AT THE SUMMIT 2025

Source text: ID:nBw9HJ6j8a

Further company coverage: LCTX.A

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Lineage Cell Therapeutics

    See all news